HDAC6 inhibitors increase efficacy of immunotherapy in triple-negative breast cancer

[News]

Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the top-tier journal Cancer Research by investigators at the George Washington University (GW) Cancer Center.

More... (https://www.news-medical.net/news/20200806/HDAC6-inhibitors-increase-efficacy-of-immunotherapy-in-triple-negative-breast-cancer.aspx)